Dr. Stephan Moll writes… Skyla® is a new intrauterine device (IUD) birth control option, approved in February 2013 by the FDA. Skyla® is like a small version of the Mirena® IUD; it releases low doses of the hormone progestin to help the IUD prevent pregnancy. It has the following features:
- It is a small, flexible plastic T-shaped device, smaller than the Mirena®.
- It contains the progestin hormone called levonorgestrel, which is released at continuous daily rate over the 3 years the IUD can stay in place.
- Given its small size, it is particularly suitable for women who have never had a child.
- And given that that progestin-releasing IUDs do not increase the risk for blood clots [ref 1], it is a particularly attractive option in women with a history of blood clots (DVT, PE, etc) or a clotting disorder (= thombophilia or hypercoagulable states), such as factor V Leiden, the prothrombin (factor II) mutation, or protein C, S or antithormbin deficiency or the antiphospholipid antibody syndrome. Thrombosis is not listed as a possible adverse outcome associated with Skyla® use.
- Commercial Skyla® website: here
- Full Skyla® prescribing information: here
- Clot Connect discussion of progestin-contraceptives: here
- van Hylckama-Vlieg A et al. The risk of deep vein thrombosis associated with injectable depot-medtoxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010(Nov);30:2297-2230.
Disclosure: I have no conflict of interest.
Last updated: June 3rd, 2013